Concepedia

Jaruwan Tubprasert

JT

Statistics

Publications

7

Citations

259

H-Index

7

Active since

2006

Affiliations

Mahidol University(Current)

University of Oxford

Mahidol Oxford Tropical Medicine Research Unit

Universidade Federal de Minas Gerais

Ministry of Public Health

Jaruwan Tubprasert is an author at Mahidol University specializing in antiviral pharmacotherapy, antiviral therapy, and virology.

Publications per year

2006–2024

7

Publications

7

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

William HK Schilling, Podjanee Jittamala, James A Watson et al. · The Lancet Infectious Diseases · 2023 · 95 citations · Full text

, , +17

<i>In Vitro</i> antimicrobial activity of <i>Zingiber cassumunar</i> (Plai) oil and a 5% Plai oil gel

Pimolpan Pithayanukul, Jaruwan Tubprasert, Mansuang Wuthi-udomlert · Phytotherapy Research · 2006 · 63 citations

, , +9

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Viravarn Luvira, William HK Schilling, Podjanee Jittamala et al. · BMC Infectious Diseases · 2024 · 29 citations · Full text

, , +17

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

Podjanee Jittamala, William HK Schilling, James A Watson et al. · The Journal of Infectious Diseases · 2023 · 28 citations · Full text

, , +16

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

William HK Schilling, Podjanee Jittamala, James A Watson et al. · eLife · 2023 · 20 citations · Full text

, , +15

1–5 of 7